A detailed history of Bio Impact Capital LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 460,617 shares of AKRO stock, worth $19.4 Million. This represents 1.92% of its overall portfolio holdings.

Number of Shares
460,617
Previous 392,544 17.34%
Holding current value
$19.4 Million
Previous $11.3 Million 13.78%
% of portfolio
1.92%
Previous 1.76%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$26.75 - $35.28 $1.82 Million - $2.4 Million
68,073 Added 17.34%
460,617 $12.8 Million
Q3 2024

Nov 12, 2024

BUY
$21.45 - $29.34 $140,583 - $192,294
6,554 Added 1.7%
392,544 $11.3 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $971,638 - $1.31 Million
53,066 Added 15.94%
385,990 $9.06 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $5.91 Million - $10.4 Million
332,924 New
332,924 $8.41 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.96B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.